LYSINE BIOTECH PRIVATE LIMITED
Product development and Manufacture of drugs, biomarkers and vaccines from Protein and DNA
CIN:U74999TN2018PTC122879
| S.No | 1.PRODUCT Small molecules based drugs delivery (IND) | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB101 Efficacy and Safety of Kilirag-1 (GLP-1) Medicines 2 mg 8 days once for Type 2 Diabetes and Obesity (IND) | 2027 | ||
| 2 | LB102 Efficacy and Safety of Kpondin1 (Spondin-1)- Medicines for Alzheimer's (IND) | 2028 |
| S.No | 2.PRODUCT 2nd,3rd,4th & 5th generation of CAR T Cells Therapy | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB201 Development of Commercial Novel huanti-CAR19T-CD27/41-BB-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety | 2027 | ||
| 2 | LB202 Development of Commercial Novel huanti-FAPCART-CD27-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety | 2029 | ||
| 3 | LB203 Development of Commercial Novel Allogenic Neoantigen hup53CART-CD27-41-BB-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety | 2029 | ||
| 4 | LB204 Development of Commercial Novel huanti-GD2CART-CD27-41-BB-NFAT-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety | 2029 | ||
| 5 | LB205 Development of Commercial Novel huanti-BCMACART-CD27-41-BB-NFAT-CD3Z Cells Therapy: Towards Enhanced Efficacy and Safety | 2028 | ||
| 6 | LB206 Development of Commercial Novel bi-cistronic huanti-GPRC5D-hCD3CART-CD27-CD28-41-BB-NFAT-CD3Z Cells Therapy by using Ribosomal skipping : Towards Enhanced Efficacy and Safety | 2029 | ||
| 7 | LB207 Development of Commercial Novel bi-cistronic huanti-CD19-20CART-CD27-CD28-41-BB-NFAT-CD3Z Cells Therapy by using Ribosomal skipping : Towards Enhanced Efficacy and Safety | 2028 | ||
| 8 | LB208 Development of Commercial Novel tri-cistronic huanti-CD19-20-22CART-CD27-CD28-41-BB-NFAT-CD3Z Cells Therapy by using Ribosomal skipping : Towards Enhanced Efficacy and Safety | 2028 |
| S.No | 3.PRODUCT Adeno-associated virus (AAV2-9) serotypes for gene therapeutics | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB301 AAV-DMD gene therapy designed to deliver a copy of the mRNA encoding the human DMD: Towards Enhanced Efficacy and Safety. | 2028 | ||
| 2 | LB302 AAV-SMN1 gene therapy designed to deliver a copy of the mRNA encoding the human SMN1: Towards Enhanced Efficacy and Safety. | 2028 |
| S.No | 4.PRODUCT LNP based mRNA Vaccine | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB401 Development of Commercial Novel: a Safe, Efficient, Dual-Use LNP based mRNA Vaccine for Humans and Animals against Rabies virus ((RABV-G) | 2028 | ||
| 2 | LB402 Development of Commercial Novel: a Safe, Efficient, LNP based mRNA Vaccine for humans against leptospirosis. | 2028 |